title: Acute effects of nasal salmon calcitonin on calcium and bone metabolism.
abstract: Effects of a single dose of 200 IU of nasal salmon calcitonin (SCT) on calcium metabolism and biochemical markers of bone turnover were investigated in 12 healthy male volunteers in a randomized, placebo-controlled, cross-over design. The nasal spray was given in the morning, and subsequently blood and urine samples were collected for 26 hours. There was a significant decrease in serum ionized calcium with a nadir 4 hours after administration of nasal SCT accompanied by a significant increase in serum parathyroid hormone (P = 0.01) and serum calcitriol (P = 0.04). Nasal SCT did not reduce urinary hydroxyproline/creatinine. Urinary deoxypyridinoline/creatinine was lowered significantly 2 hours after administration of nasal SCT and throughout the first 24 hours, but remained unchanged for the last 2 hours. On a 24-hour basis, urinary deoxypyridinoline/creatinine decreased from 14.1 (3.5) nmol/mmol to 11.7 (3.2) nmol/mmol after nasal SCT (P = 0.04). Nasal SCT did not change the serum levels of alkaline phosphatase, osteocalcin, and the carboxyterminal propeptide of type 1 procollagen. The results indicate that nasal SCT given as a single dose provokes a modest decrease in bone resorption lasting several hours, but leaves bone formation unaffected.
authors.affiliation: Medical Department, Sundby Hospital, Copenhagen, Denmark.
authors.forename: G
authors.initials: G
authors.lastname: Thamsborg
authors.forename: S G
authors.initials: SG
authors.lastname: Skousgaard
authors.forename: H
authors.initials: H
authors.lastname: Daugaard
authors.forename: S
authors.initials: S
authors.lastname: Schifter
authors.forename: G
authors.initials: G
authors.lastname: Kollerup
authors.forename: O H
authors.initials: OH
authors.lastname: Sørensen
mesh_terms: D000281:Administration, Intranasal; D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood; D000596:Amino Acids / Q000652:urine; D000818:Animals; D015415:Biomarkers / Q000097:blood / Q000652:urine; D001862:Bone Resorption / Q000517:prevention & control; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism*; D002116:Calcitonin / Q000008:administration & dosage*; D002118:Calcium / Q000378:metabolism*; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D008297:Male; D015675:Osteocalcin / Q000097:blood; D010012:Osteogenesis / Q000187:drug effects; D010446:Peptide Fragments / Q000097:blood; D011347:Procollagen / Q000097:blood; D012474:Salmon
chemical_list: D000596:Amino Acids; D015415:Biomarkers; D010446:Peptide Fragments; D011347:Procollagen; C042813:procollagen type I carboxy terminal peptide; D015675:Osteocalcin; C028815:salmon calcitonin; C036020:deoxypyridinoline; D002116:Calcitonin; D000469:Alkaline Phosphatase; D006909:Hydroxyproline; D002118:Calcium